Ilaria Marcianò, Ylenia Ingrasciotta, Francesco Giorgianni, Valentina Ientile, Alessandro Chinellato, Daniele Ugo Tari, Rosa Gini, Salvatore Cannavò, Maurizio Pastorello, Salvatore Scondotto, Pasquale Cananzi, Giuseppe Traversa, Francesco Trotta, Valeria Belleudi, Antonio Addis, Gianluca Trifirò
Purpose: Somatropin [recombinant growth hormone (rGH)] is approved in children and adults for several conditions involving growth disturbances and the corresponding biosimilar is available in Italy since 2006. No population-based data are available on the pattern of rGH use in Italian clinical practice. This study aimed at exploring the pattern of biosimilar and originator rGH use in six Italian centers, where different policy interventions promoted biosimilar use. Methods: This population-based, drug-utilization study was conducted in the years 2009-2014, using administrative databases of Umbria, Tuscany, and Lazio Regions and Local Health Units of Caserta, Treviso, and Palermo...
2018: Frontiers in Endocrinology